Objectives. To identify novel serum protein biomarkers and establish diagnostic pattern for rheumatoid arthritis (RA) by using proteomic technology. Methods. Serum proteomic spectra were generated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) combined with weak cationic exchange magnetic beads. A training set of spectra, derived from analyzing sera from 22 patients with RA, 26 patients with other autoimmune diseases and 25 ageand sex-matched healthy volunteers, was used to train and develop a decision tree model with a machine learning algorithm called decision boosting. A blinded testing set, including 21 patients with RA, 24 patients with other autoimmune diseases and 25 healthy people, was used to examine the accuracy of the model. Results. A decision tree model was established, consisting of four potential protein biomarkers whose m/z values were 4966.88, 5065.3, 5636.97 and 7766.87, respectively. In validation test, the decision tree model could differentiate RA from other autoimmune diseases and healthy people with the sensitivity of 85.71% and specificity of 87.76%, respectively. Conclusions. The present data suggested that MALDI-TOF-MS combined with magnetic beads could screen and identify some novel serum protein biomarkers related to RA. The proteomic pattern based on the four candidate biomarkers is of value for laboratory diagnosis of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease with persistent inflammation of multiple synovial joints, which results in progressive and irreversible tissue destruction of bone and cartilage (1) . Consequently, patients with RA commonly suffer from joint deformity as well as joint dysfunction. Accurate diagnosis and proper treatment are therefore crucial for enhancing curative effects and improving life quality of RA patients. For many years, laboratory diagnosis of RA has relied on the detection of rheumatoid factor (RF), one of autoantibodies. However, this diagnostic test performs poorly with moderate sensitivity and low specificity (2) . Although a new assay that detects antibodies to citrullinated peptides, called the anti-CCP assay, has a much higher specificity (>97%) (3) than the RF test, its sensitivity (68%) is still not satisfactory. Anti-keratin antibodies detection that is also commonly performed in laboratory is of similar clinical value with anti-CCP assay, and simultaneously detecting these three antibodies can improve the diagnosis of RA. However, all these laboratory diagnostic methods are still not perfect enough, and identifying novel biomarkers with high specificity and sensitivity is necessary for improving the diagnosis of RA.
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) is an important proteomic technology, which has been used for analyzing serum proteomic spectra. Based on this technology, many protein biomarkers of certain diseases have been discovered (4) (5) (6) . Magnetic beads have large surface so that they can capture more smallmolecular peptides and proteins when compared with conventional protein chips (7, 8) . The combination of MALDI-TOF-MS and magnetic beads can take advantages of each other, and it can detect more proteins of low molecular weight.
In this study, we used MALDI-TOF-MS combined with weak cationic exchange (WCX) magnetic beads to detect serum proteome of 43 patients with RA, 50 patients with other autoimmune diseases [19 with systemic lupus erythematosus (SLE), 15 with Sjogren's syndrome (SS) and 16 with systemic scleroderma (SSc)] and 50 healthy volunteers. Based on these data, we aimed to discover some novel potential biomarkers for RA and then established a diagnostic model in order to improve diagnostic efficiency for RA.
Methods

Patients and controls
This study was approved by the Ethics Committee of the Chinese Human Genome and the Ethics Committee of West China Hospital, and written informed consent was obtained from all participants. A total of 143 serum samples were included in this study, among which, there were 43 from patients with RA, 50 from patients with other autoimmune diseases (19 with SLE, 15 with SS and 16 with SSc) as disease control (DC) and 50 from healthy volunteers as healthy control (HC). All samples were collected at West China Hospital of Sichuan University and Peking Union Medical College Hospital from April 2006 to December 2007. All the patients were diagnosed according to the latest diagnosis criteria of American Rheumatism Association. Demographic features of all the patients and healthy volunteers were provided in Table 1 and sample numbers used for profiling (training set) and validation (blinded testing set) were listed in Table 2 Serum samples. For all patients and control subjects, a 4-ml fasting blood sample was drawn into a BD Vacutainer tube without anticoagulant at 8:00-9:00 a.m., left to clot at room temperature for up to 1 h and then centrifuged at 3000 g for 5 min at room temperature. Then sera were divided into aliquots and stored at À80°C until analysis. The mean storage time for each study group was shown in Table 3 . All serum samples from the diseased and control groups were randomized, and the investigator was blinded to their identity.
Magnetic beads-based activation. WCX magnetic beads were used for serum foreprocess and they need activating. First, 50-ll WCX magnetic beads (50 mg ml À1 ) were transferred into a PCR tube that was placed in a 2 3 8-well magnetic bead separator (MBS) device for 1 min for magnetic fixation of the WCX particles. Then, the supernatant was aspirated and the tubes were removed from the MBS device. One hundred microliters binding buffer (50 mM sodium acetate, pH 4.0) was added and carefully mixed with the magnetic beads. After that, the tube was replaced in the MBS device and moved back and forth sequentially between adjacent wells on each side of the magnetic bar in the MBS device. This facilitated washing of the magnetic particles as they were fixed to the tube wall, moved through the washing solution in succession. After fixation of the magnetic beads for 1 min in the MBS device, the supernatant was aspirated. This washing procedure was repeated twice. Finally, the magnetic beads were well prepared for reacting with serum proteins.
MALDI ProteinChip binding.
Before reacting with magnetic beads, sample serum was needed to be diluted. Firstly, 10 ll serum and 20 ll U9 lysis solution (9 M urea, 20 g l À1 CHAPS, 10 g l À1 DTT, 50 mM Tris-HCl, pH 9.0) were transferred to a 0.5-ml centrifuge tube. The serum and solution were mixed and then incubated for 30 min at 4°C. Secondly, 370 ll binding buffer was added to make 40-fold dilution of the serum. After the foreprocess, 100 ll 40-fold diluted serum was added and mixed carefully with the activated magnetic beads, incubated for 1 h at 4°C and washed twice with 100 ll binding buffer. When the final washing step finished, bound molecules were eluted by incubation with 10 ll 0.5% (v/v) TFA. Then, the elute (5 ll) was diluted 2-fold by adding 5 ll SPA (50% ACN + 0.5% TFA). The diluted elute (1 ll) was aspirated and spotted onto an 8-spot prestructured sample chip (Au-chip, Ciphergen Company) and left to dry at room temperature. Finally, protein crystal on the chip was to be detected by MALDI-TOF MS.
MALDI-TOF-MS analysis. Prepared Au-chips were placed on the PBS IIc mass spectrometer reader (Ciphergen Company), and time-of-flight spectra was generated by averaging 80 laser shots collected on each spot at laser intensity 205 and detector sensitivity 8. The optimization range was from 2000 to 30 000 (m/z), high mass-charge ratio was 50 000. Mass accuracy was calibrated externally by standard procedures using the all-in-one peptide molecular mass standards (Ciphergen Company).
Data collecting and collating. The data collating involved three stages: (i) peak detection and alignment, (ii) selection of differently expressed peaks among the three groups that may represent potential biomarkers of RA and (iii) data analysis using a decision tree algorithm. Peak detection was performed by using Ciphergen ProteinChip software 3.0.2 (Ciphergen Company). The protein peaks with m/z ranging from 2000 to 50 000 were selected for analysis, while those with m/z ranging between 0 and 2000 were eliminated from analysis to avoid interference from adducts, artifacts of the energy-absorbing molecules and other possible chemical contaminants. Peak detection involved (i) baseline subtraction, (ii) mass accuracy calibration and (iii) automatic peak detection. Using Biomarker Wizard Version 3.1.0 (Ciphergen Company), biomarkers were generated that represent consistent protein peak sets across multiple spectra. Baseline subtraction was performed on all spectra. Mass/charge 4901 peak was selected to normalize dimension. The settings for auto detect peaks to cluster were as follows: signal-to-noise ratio was 5 and minimum peak threshold was 10% for the first pass; for cluster completion, cluster mass window was 0.3% and signal-to-noise ratio for the second pass was 2.
Differently expressed peaks were selected by the differences in protein peak intensities between groups using the Biomarker Wizard Version 3.1.0, which used the nonparametric Kruskal-Wallis test and Mann-Whitney test.
Construction of the decision tree classification algorithm was performed by Biomarker Patterns Software 5.0 (BPS; Ciphergen Company). BPS is an implementation of the Classification and Regression Trees decision tree system developed by Breiman et al. (9) . BPS uses the peak information generated by the training set of known samples to build a binary decision tree algorithm. The algorithm functions by assigning each sample in the data set into one of two nodes with a rule based on the intensity of a particular peak or splitter (10, 11) .
To minimize potential bias that would affect the accuracy of results, all procedures including sample pretreatment and MALDI-TOF-MS analysis were performed by a special technician and all samples from patients and control groups were processed in the same way. Analysis of all samples was completed within 5 days.
Statistical analysis
The spectra of 143 serum samples were separated by a stratified random sampling into 'training set' data (a total of 73, 22 RA, 10 SLE, 9 SS, 7 SSc and 25 healthy volunteer samples) and 'blinded testing set' data (a total of 70, 21 RA, 9 SLE, 6 SS, 9 SSc and 25 healthy volunteer samples). The training set data were used for developing a boosting decision classification, which could screen specific protein biomarkers and accordingly establish a diagnosis model of RA. The resulting boosting decision tree classification was then applied to the blinded testing set data for evaluating the accuracy of the decision tree model.
All the results were expressed as 'mean 6 SD' and P values <0.05 were considered statistically significant.
Results
Identification of serum protein spectra
Protein spectra of 143 serum samples were detected by MALDI-TOF-MS combined with WCX magnetic beads. The combination was particularly effective in resolving proteins and peptides of low molecular weight (Fig. 1) .
Comparison of serum protein spectra between RA and control subjects (disease controls and healthy controls)
A total of 102 protein peaks were detected by MALDI-TOF-MS in the training set including 22 RA, 26 DC and 25 HC, and 34 of the 102 peaks in RA were different from that in control groups (P < 0.05). Furthermore, among the 34 differential protein peaks, 9 were over-expressed and 25 were down-regulated in RA objects.
Screening of serum protein biomarkers of RA and construction of boosting decision tree
The initial data of serum protein peaks of training set group were processed by the Biomarker Wizard Version 3.1.0 Software. After that, the construction of the decision tree classification algorithm was performed by BPS (Ciphergen Biosystems, Inc.) using the processed data. The BPS produced many decision trees and evaluated the error cost (represented as 'relative cost' in the software) for each tree. Of the classification trees analyzed by BPS software, the most optimal classification tree with the lowest error cost (relative cost being 0.135 and BPS settings as follows: method = 1.50, advanced = 10 and testing = 18) was eventually established, and 4966.88, 5065.3, 5636.97 and 7766.87 (m/z) peaks were selected as the best biomarkers of RA in the classification tree. The protein peak m/z Biomarkers discovery of RA by MALDI-TOF-MS 613 4966.88 was over-expressed, while m/z 5065.3, 5636.97 and 7766.87 were down-regulated in RA group compared with control groups (Fig. 2) . All 73 training set serum samples were differentiated into seven terminal nodes according to the logical relationship within the tree (Fig. 3) . Samples differentiated into terminal nodes 1 and 4 were assigned to RA; terminal nodes 3 and 6 to DC and terminal nodes 2, 5 and 7 to HC. For example, there was an unknown sample with protein peak m/z 5065.3 (intensity < 1.241) and m/z 4966.88 (intensity > 6.618); then, the sample was placed in terminal node 4 and it would be classified as RA. If the sample was placed in terminal node 7, then it would be assigned to HC. Based on the stochastic nature of reality, the possibility of misclassification of a new sample cannot be ruled out even for a pure node that contains only one sample type. To make sure that whether an unknown sample could be classified correctly or not, the expected probability was calculated for each class in the seven terminal nodes (Table 4) . For example, the expected probability for HC samples to be misclassified as RA in terminal node 4 is 4.5%, whereas there was 86.4% chance for RA specimens to be correctly classified to terminal node 4. The corresponding Receiver Operating Characteristics curve of the optimal decision tree was also supplied by the Biomarker Patterns Software 5.0. The Receiver Operating Characteristics integral was 0.983 (Fig. 4) . Besides, statistical analysis showed that the sensitivity and specificity of this decision tree model in training set group were 86.36% and 92.16%, respectively.
Diagnostic characteristics of the decision tree model
The accuracy of the boosting decision tree model for recognizing RA among people with other autoimmune diseases and healthy individuals was generated by the comparison between the decision tree judgment and the clinical diagnosis of each sample. In the training set group, the decision tree could identify 19 of 22 RA, 24 of 26 other autoimmune diseases and 23 of 25 healthy people, which suggested a high accuracy in identifying RA patients and control subjects. Results of validation test performed in the blinded set group showed that the decision tree could differentiate RA, other autoimmune diseases and healthy people with the accuracy of 85.7, 87.5 and 88.0%, respectively (Table 5 ). In the blinded set group, the decision tree model showed lower sensitivity and specificity than that in the training set group, which were 85.71 and 87.76%, respectively.
Discussion
Nowadays, the diagnosis of RA is mainly based on clinical symptoms and some laboratory indices such as RF, C-reactive protein, erythrocyte sedimentation rate and anti-CCP antibodies. However, these approaches are not effective in accurately diagnosing RA. In our study, we described the application of a new technology, MALDI-TOF-MS combined with magnetic beads, in identifying biomarkers and diagnosing RA.
Proteomic pattern analysis is one of the most promising approaches for the discovery and subsequent identification of proteins and peptides associated with various diseases (4) (5) (6) 12) . The capability of MALDI-TOF-MS to detect lowmolecular weight peptides and proteins has helped to open a new realm of plasma components, comprising the fragmentome or peptidome, which were largely overlooked by traditional techniques. Furthermore, magnetic bead purification for the analysis of low-abundance proteins in the blood or body fluids can facilitate identifying new candidate biomarkers by MALDI-TOF-MS. Generally, protein profiling by MALDI-TOF-MS after proteome fractionation with magnetic beads is a robust, precise and high-throughput technique for the investigation of complex blood samples (13) . For these reasons, MALDI-TOF-MS combined with magnetic beads is being applied widely to analyze potential disease markers in serum or plasma specimens.
Although proteomic technology has been applied to identify novel biomarker in various diseases including cancer, cardiovascular diseases, some autoimmune diseases such as SLE and Sjö gren's syndrome and so on (14-18), the application of proteomics in RA is still in its infancy. Several discriminating acute-phase proteins have been identified in serum, plasma and synovial fluid of patients with different rheumatic pathologies using classic proteomic approaches (19) (20) (21) (22) (23) . Serum amyloid A protein is present in the synovial fluid and plasma of RA patients, but it is undetectable in plasma or synovial fluid of osteoarthritis (OA) patients. This acute-phase protein plays a crucial role in the early organization of host defense, but it might have a destructive effect in chronic inflammation (21) . Certain fibrinogen isoforms and the calgranulin protein isoforms have been suggested to have a disease-associated expression or processing in biological fluid matrices of RA and OA patients (21, 23) . However, to our knowledge, there is no study about scanning biomarkers of RA patients and establishing a diagnostic mode for RA by proteomic technique remains. In our study, 34 proteins were identified with discrepancy between RA patients and control objects by using MALDI-TOF-MS coupled with WCX magnetic beads, which suggested that a wide range of proteins might be involved in disorder of humoral immunity. These proteins could be those already known ones such as RF, anti-CCP antibodies and complements, although there could also be some unidentified proteins whose roles in the pathogenesis of RA remained obscure. With the identification of 34 protein peaks, the potential protein biomarkers may be used to diagnose RA.
With the help of Biomarker Patterns Software, the optimal boosting decision tree was established by analyzing 'training set' data. Judgment rules within this tree generated by the software well formed a model for recognizing RA. This model could provide one of the three following results including 'RA sample', 'other autoimmune diseases sample' and 'normal sample' for an unknown sample. 
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Since a test specimen cannot be identified as a RA sample with 100% accuracy, we thus calculated the expected probabilities to predict the chance of a sample being classified correctly or misclassified. Data showed that the chance of RA samples being misclassified into the HC terminal node was only 4.3%, and it did not affect the efficiency of this decision tree model for RA diagnosis. 'Blinded testing set' data were used for validating the performance of the decision tree model in diagnosing RA, and the results suggested that the diagnostic model could effectively distinguish RA patients from individuals with other autoimmune diseases or healthy people. Compared with anti-CCP assay, this decision tree model had a comparable specificity (87.76%) but a higher sensitivity (85.71%) in diagnosing RA. Therefore, the good performance indicates that this decision tree model could be a potential diagnostic tool for RA.
Four protein peaks at m/z 4966.88, 5065.3, 5636.97 and 7766.87 were members of the decision tree. Among the four, the protein peak m/z 4966.89 was over-expressed in RA cases, which may help to enhance the immune response of RA patients. On the contrary, the other three protein peaks were down-regulated in RA, which possibly contribute to suppressing overreactive immune response. The disorder of these proteins may play a critical role in promoting dysfunction of the autoimmune system. However, MALDI-TOF-MS cannot identify proteins or allow for absolute protein quantification. In this context, identifying the protein species represented by the peaks on the spectra would provide further evidences that they are indeed biologically meaningful molecules related to RA. Therefore, our further work will include searching the empirical proteomic ontology knowledge base to identify these differential proteins and then validating them by western blot or ELISA. Fig. 3 . The boosting decision tree classification of RA, DC and HC samples in the training set. The root node (top) and descendant nodes were shown as ellipses, and the terminal nodes (nodes 1-7) were shown as rectangles. The mass value in the nodes was followed by lower or equal to intensity value. If the answer to the question in a node of the tree is yes, you proceed down to the left node, otherwise (i.e. no), you proceed down to the right node. When proceeding to the terminal nodes, the decision tree assigned samples to three groups. Samples in terminal nodes 1 and 4 were assigned to RA, terminal nodes 3 and 6 were to DC and terminal nodes 2, 5 and 7 were to HC. The number in rectangles represented the actual clinical diagnosis of samples assigned to this terminal node by decision tree (i.e. in terminal node 4, decision tree assigned 19 samples to RA, but actually, 1 of them were DC according to the clinical diagnosis). Biomarkers discovery of RA by MALDI-TOF-MS 617 magnetic beads and Biomarker Patterns Software. This diagnostic model comprised four proteins that may be helpful in accurately diagnosing RA, and further identification of these four proteins may have important therapeutic implications for RA patients.
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